Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells.
Phenylacetate, a natural metabolite of phenylalanine which was originally described as a plant growth hormone, has recently gained attention as a possible differentiation inducer for a variety of human tumor cell types. This interest prompted us to assess the ability of sodium phenylacetate (NaPA) to promote the differentiation of human neuroblastoma cells, both alone and in combination with retinoic acid (RA), a known inducer of neuroblastoma differentiation and maturation. Using the LA-N-5 cell line, we have determined that NaPA can stimulate the differentiation of neuroblastoma cells, as evidenced by dose-dependent inhibition of cell proliferation, neurite outgrowth, increased acetylcholinesterase activity and reduction of N-myc expression. Furthermore, NaPA and RA synergized in inducing differentiation, in that combination treatment resulted in cessation of cell growth along with morphologic and biochemical changes indicative of the loss of malignant properties. We have determined that NaPA can markedly enhance mRNA levels of the nuclear RA receptor-beta (RAR beta) in LA-N-5 cells prior to morphologic or other phenotypic changes induced by this compound. This effect appeared to be distinct from the ability of NaPA to alter tumor cell lipid metabolism via inhibition of protein isoprenylation. Thus among its varied effects on LA-N-5 cells, NaPA appears to interact with the RA pathway at the nuclear level by up-regulating RAR beta expression.
Sidell
N
N
Department of Pathology and Laboratory Medicine (Neuropathology), UCLA School of Medicine 90024.
Wada
R
R
Han
G
G
Chang
B
B
Shack
S
S
Moore
T
T
Samid
D
D
D002454:Cell Differentiation / Q000187:drug effects*; D002455:Cell Division / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D016259:Genes, myc; D005973:Glutamine / Q000378:metabolism; D006801:Humans; D007124:Immunoenzyme Techniques; D016501:Neurites / Q000187:drug effects / Q000502:physiology; D009447:Neuroblastoma / Q000473:pathology*; D010648:Phenylacetates / Q000494:pharmacology*; D017368:Protein Prenylation; D016271:Proto-Oncogene Proteins c-myc / Q000096:biosynthesis; D018168:Receptors, Retinoic Acid / Q000096:biosynthesis; D014212:Tretinoin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects; D015854:Up-Regulation
D010648:Phenylacetates; D016271:Proto-Oncogene Proteins c-myc; D018168:Receptors, Retinoic Acid; D005973:Glutamine; D014212:Tretinoin; C025136:phenylacetic acid